All In Biotech

Drug Trial Radar · NCT04312347

Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels

Tamoxifen Dose Adjustment on ER+ Breast Cancer Patients Based on Genomic and Metabolite Concentrations Analysis

Last checked: Nov 19, 2026Latest source record: Aug 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

151

Actual

Start

Sep 6, 2019

Primary completion

May 1, 2021

Study completion Jun 30, 2021

Sponsor

Lead sponsor
Nalagenetics Pte LtdIndustry
Sponsor type
Industry
First posted
Mar 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study is to perform CYP2D6 genotyping and metabolite concentrations analysis on ER+ breast cancer patients who are taking tamoxifen and give dose recommendations based on the CYP2D6 genotypes and endoxifen levels.

Conditions

  • ER+ Breast Cancer

Interventions

  • Tamoxifen dose adjustmentDrug

    Patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype will receive tamoxifen dose escalation into 40 mg/day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effects of genotype and phenotype of CYP2D6 on plasma and serum concentration of tamoxifen and its metabolitesTime frame: 8 weeks after initial tamoxifen intake
  2. Effects of dose recommendation of tamoxifen based on CYP2D6 genotyping results on endoxifen levelsTime frame: 8 weeks after dose recommendation
  3. Frequencies of CYP2D6 alleles in female Indonesian populationTime frame: Baseline, pre-intervention

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MRCCC Siloam Hospital Semanggi

    Jakarta, DKI Jakarta, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.